Neoadjuvant Chemotherapy in Oesophageal Adenocarcinoma – Authors' Reply

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(17)30776-3
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

Neoadjuvant Chemotherapy in Oesophageal Adenocarcinoma

The Lancet Oncology
Oncology
2017English

Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma Following Neoadjuvant Chemotherapy: Which Scoring System to Use?

ISRN Pathology
2012English

Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Letter: Studies of Salivary Pepsin in Patients With Gastro-Oesophageal Reflux Disease. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Editorial: Oesophageal Dilation in Eosinophilic Oesophagitis-Can and Should, but When and How? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

New Developments in Oesophageal Adenocarcinoma Treatment

European Oncology and Haematology
OncologyHematology
2008English

Authors’ Reply

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2019English

Authors' Reply

Journal of the American Society of Echocardiography
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2019English

Authors' Reply:

British Journal of Psychiatry
MedicinePsychiatryMental Health
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy